Published in Circulation on June 01, 1995
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest (1998) 5.95
Growth factor therapies for vascular injury and ischemia. Circulation (1995) 1.42
Chronic hindlimb ischemia impairs functional vasodilation and vascular reactivity in mouse feed arteries. Front Physiol (2011) 0.82
Autologous bone-marrow mesenchymal stem cell implantation and endothelial function in a rabbit ischemic limb model. PLoS One (2013) 0.82
Mitotic and antiapoptotic effects of nanoparticles coencapsulating human VEGF and human angiopoietin-1 on vascular endothelial cells. Int J Nanomedicine (2011) 0.81
Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res (1999) 11.32
Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med (1999) 10.16
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med (1999) 9.18
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J (1999) 6.62
Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A (2000) 6.59
VEGF is required for growth and survival in neonatal mice. Development (1999) 6.16
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest (1998) 5.95
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A (1995) 5.92
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest (2000) 5.78
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem (1992) 4.92
Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res (1999) 4.68
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem (1994) 4.41
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell (1993) 4.33
Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet (1996) 4.32
Mouse model of angiogenesis. Am J Pathol (1998) 4.28
Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation (2001) 4.17
Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation (1998) 4.10
The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85
Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins (1977) 3.80
Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res (1998) 3.79
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 3.78
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther (1990) 3.55
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest (1995) 3.52
Age-dependent impairment of angiogenesis. Circulation (1999) 3.47
Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature (2001) 3.42
Structural characterization and biological functions of fibroblast growth factor. Endocr Rev (1987) 3.40
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res (2000) 3.39
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A (1993) 3.01
Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem (1997) 2.95
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol (1996) 2.95
Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation (1999) 2.92
Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem (2000) 2.87
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest (1999) 2.86
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol (1999) 2.83
Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem (2000) 2.80
Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation (1996) 2.79
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem (1996) 2.75
Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med (1997) 2.73
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol (1994) 2.66
Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol (2001) 2.49
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun (1992) 2.47
Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development (2000) 2.43
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 2.41
A new murine model of accelerated senescence. Mech Ageing Dev (1981) 2.40
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst (2001) 2.27
Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun (1991) 2.25
Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation (1998) 2.25
Evidence implicating nonmuscle myosin in restenosis. Use of in situ hybridization to analyze human vascular lesions obtained by directional atherectomy. Circulation (1992) 2.20
HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest (2001) 2.20
Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem (1995) 2.20
Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest (1992) 2.19
Acute cardiac events temporally related to cocaine abuse. N Engl J Med (1986) 2.18
Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut (2007) 2.15
Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol (1992) 2.14
Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med (2000) 2.13
Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem (1998) 2.12
Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation (2000) 2.12
VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest (1999) 2.08
Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation (1994) 2.08
Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation (1995) 2.07